A growing number of drugs in the development pipeline are poorly soluble in gastrointestinal fluids, and can severely limit oral bioavailability. This talk describes how an amorphous solid dispersion (ASD) of acalabrutinib was designed using in vitro studies and in silico modeling. Watch now to understand how ASD formulations can enhance bioavailability.
Content Type: Presentation (on-demand)
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center